PDT Partners’s Novavax NVAX Stock Holding History

PDT Partners’s Portfolio NVAX Stock Details NVAX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-12,088	Closed	-$124K	–	672
2022 Q4	$124K	Sell	12,088 -6,412	-35%	-$113K	0.02%	570
2022 Q3	$337K	Buy	+18,500	New	+$802K	0.05%	549
2022 Q2	–	Sell	-3,302	Closed	-$243K	–	1093
2022 Q1	$243K	Buy	+3,302	New	+$294K	0.02%	780
2021 Q4	–	Sell	-2,000	Closed	-$415K	–	972
2021 Q3	$415K	Buy	+2,000	New	+$441K	0.03%	517
2015 Q3	–	Sell	-8,741	Closed	-$1.95M	–	1470
2015 Q2	$1.95M	Buy	8,741 +4,989	+133%	+$877K	0.05%	440
2015 Q1	$621K	Buy	+3,752	New	+$609K	0.02%	939

Other funds holding NVAX

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

SCM

Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Citigroup New York $235B AUM 32.99% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

PDT Partners's NVAX Position: Q1 2023 in Review

PDT Partners sold out of Novavax (NVAX) in Q1 2023, closing a stake of 12,088 shares — an estimated $124K sold.

PDT Partners first reported a position in NVAX in Q1 2015 and held it in 6 quarters. The position peaked at $1.95M in Q2 2015. 222 funds tracked by Wall St. Rank hold NVAX as of Q1 2023.

PDT Partners reported no remaining Novavax position as of Q1 2023 after selling out during the quarter.
PDT Partners sold 12,088 Novavax shares in Q1 2023, an estimated $124K.
PDT Partners first reported a position in Novavax in Q1 2015 and held it in 6 quarters.
PDT Partners's Novavax position peaked at $1.95M in Q2 2015.
222 funds tracked by Wall St. Rank held Novavax as of Q1 2023.

Based on PDT Partners's 13F filing for Q1 2023, filed 15 May 2023.